CNTY-101 is under clinical development by Century Therapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition ...
NKX-019 is under clinical development by Nkarta and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR ...
A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...